mental health

News

atai invests $50m in Beckley Psytech

Beckley Psytech has announced that it has received substantial strategic investment from Germany-based atai Life Sciences, totalling $50 million, to accelerate the clinica

Patients

Navigating transplant networks: Ensuring equitable access an...

Over three million people live with kidney disease in the UK. Some will progress to end-stage kidney disease, which is ultimately fatal, without either dialysis or kidney transplant.

Market Access

What the FDA’s groundbreaking guidance really means for psyc...

Mental health care is fraught with treatment-resistant conditions and ineffective or side-effect-ridden therapies.1 Psychedelic therapy, once relegated to the fringes of medical

R&D

Reducing the stigma attached to psychedelics

It’s no secret that 2023 has been a year for a shift in thinking when it comes to psychedelics, in particular as pertains to their use for hard-to-treat or treatment resistant mental health

Digital

How big pharma cares for its own

Pharma companies have a mission to help their customers stay healthy. But what about their employees?

News

Big Health buys teen depression DTx developer Limbix

In another example of consolidation in the digital therapeutics (DTx) category, Big Health has agreed to buy Limbix, adding its app for adolescents and young adults with s